Difficulty: Medium
Average Score: 92%
Practice
The drug of choice for hypoparathyroidism is
Correct answer
C
Rationale
In the treatment of hypoparathyroidism, the correct drug of choice is Vitamin D (Option C). The rationale behind this choice lies in the pathophysiology of hypoparathyroidism. In this condition, there is a deficiency of parathyroid hormone (PTH), which leads to low calcium levels in the blood. Vitamin D plays a crucial role in calcium homeostasis by enhancing calcium absorption in the gut. Administering Vitamin D helps to increase calcium levels in the blood, thereby addressing the underlying issue in hypoparathyroidism.
Option A, Parathormone, might seem like a logical choice since it directly addresses the deficiency of PTH. However, in clinical practice, Vitamin D is preferred over Parathormone due to its effectiveness in increasing calcium levels and its ease of administration.
Option B, Calcium lactate, provides exogenous calcium but does not address the underlying cause of the hypocalcemia in hypoparathyroidism. It can be used as an adjunct therapy but is not the primary treatment.
Option D, Pamidronate, is a bisphosphonate drug used to treat conditions of high calcium levels or bone disorders like osteoporosis. It is not indicated for hypoparathyroidism as it does not address the low calcium levels seen in this condition.
In an educational context, understanding the rationale behind the choice of Vitamin D for hypoparathyroidism is essential for healthcare professionals, especially those in endocrinology and pharmacology. It highlights the importance of addressing the underlying pathophysiology of a condition when selecting the appropriate pharmacological treatment. This knowledge ensures optimal patient care and treatment outcomes.
Option A, Parathormone, might seem like a logical choice since it directly addresses the deficiency of PTH. However, in clinical practice, Vitamin D is preferred over Parathormone due to its effectiveness in increasing calcium levels and its ease of administration.
Option B, Calcium lactate, provides exogenous calcium but does not address the underlying cause of the hypocalcemia in hypoparathyroidism. It can be used as an adjunct therapy but is not the primary treatment.
Option D, Pamidronate, is a bisphosphonate drug used to treat conditions of high calcium levels or bone disorders like osteoporosis. It is not indicated for hypoparathyroidism as it does not address the low calcium levels seen in this condition.
In an educational context, understanding the rationale behind the choice of Vitamin D for hypoparathyroidism is essential for healthcare professionals, especially those in endocrinology and pharmacology. It highlights the importance of addressing the underlying pathophysiology of a condition when selecting the appropriate pharmacological treatment. This knowledge ensures optimal patient care and treatment outcomes.